



# LOTEMAX<sup>®</sup> GEL

loteprednol etabonate  
ophthalmic gel 0.5%



**LOTEMAX<sup>®</sup> Gel: A proven option to treat patients with post-operative inflammation and pain following cataract surgery.<sup>1</sup>**

LOTEMAX<sup>®</sup> Gel (loteprednol etabonate ophthalmic gel 0.5% w/w) is indicated for the treatment of post-operative inflammation and pain following cataract surgery.<sup>1</sup>

### Product Specifications:

<b>Active Ingredient*</b>	The first loteprednol etabonate as a gel <sup>2,*</sup>
<b>Preservatives*</b>	Includes 0.003% BAK (70% less preservative than suspension)
<b>Formulation*</b>	Contains glycerin and propylene glycol, lubricants/moisturizers added to provide enhanced comfort <sup>1</sup> Polycarboxophil-based <sup>2</sup> continuous phase formulation: gel at rest, viscous fluid on the eye <sup>1</sup>
<b>Shaking Required*</b>	No <sup>1</sup>
<b>Drug Distribution*</b>	Uniform throughout the gel <sup>1,3,4</sup>
<b>pH*</b>	Adjusted pH of 6–7 <sup>2</sup>

Product	Size	B+L SKU #
LOTEMAX <sup>®</sup> Gel	5 g	AC50307

UPC Code	List Price per Unit
0 24208 50307 1	\$22.00

Wholesale Order Numbers		Pharmacy Order Numbers
Kohl & Frisch 152761	McKesson 81763	Shoppers Drug Mart 0 24208 50307 1

Adapted from Product Monograph

\* Clinical and/or comparative clinical significance has not been established.

BAK = benzalkonium chloride

- LOTE<sup>®</sup> has not been studied in patients <18 years of age and should not be used in this population.

Consult the complete Product Monographs at <http://www.bausch.ca/Portals/59/Files/Monograph/Pharma/Lotemax-gel-pm.pdf> for important information about:

- Contraindications in patients with suspected or confirmed infections of the eye or hypersensitivity to LOTE<sup>®</sup> or any ingredient in the formulation or container, or to other corticosteroids;
- Use in pregnant or nursing women, pediatric and geriatric patients;
- Relevant warnings and precautions regarding potential complications with prolonged use, intraocular pressure monitoring, and contact lens wearers;
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling 1-888-459-5000.

**For more information about the LOTE<sup>®</sup> Franchise, please call Customer Service at 1-800-686-7720 (English) or 1-800-686-0002 (French).**

**References:** 1. LOTE<sup>®</sup> [Gel] Product Monograph, Bausch & Lomb Inc., December 22, 2014. 2. Data on File, Medical Letter, Bausch & Lomb Inc., May 7, 2015. 3. Marlowe ZT, Davio SR. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). *Clin Ophthalmol.* 2014;8:23-9. 4. Coffey MJ, Decory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. *Clin Ophthalmol.* 2013;7:299-312.

**BAUSCH + LOMB**

Bausch & Lomb Canada, Vaughan, Ontario L4K 4B4

© Valeant Canada LP

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.




**LOTE<sup>®</sup> GEL**  
loteprednol etabonate  
ophthalmic gel 0.5%